Skip to main content
Erschienen in: Diabetologia 10/2006

01.10.2006 | Article

Insulin sensitisation affects lipoprotein lipase transport in type 2 diabetes: role of adipose tissue and skeletal muscle in response to rosiglitazone

verfasst von: G. D. Tan, G. Olivecrona, H. Vidal, K. N. Frayn, F. Karpe

Erschienen in: Diabetologia | Ausgabe 10/2006

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

Lipoprotein lipase (LPL) is produced by adipose tissue and skeletal muscle, but acts on plasma lipoproteins after being transported to endothelial binding sites. Insulin resistance is associated with decreased plasma LPL mass. We investigated the effects of insulin sensitisation on tissue-specific LPL expression and transport in patients with type 2 diabetes.

Materials and methods

Arterio-venous gradients of plasma LPL activity and mass across adipose tissue and skeletal muscle were measured in 16 type 2 diabetic patients in a double-blind, placebo-controlled, cross-over randomised trial of rosiglitazone. In vivo LPL rate of action was assessed by tissue-specific arterio-venous triglyceride concentration gradients. LPL mRNA was quantified in adipose tissue and skeletal muscle biopsies.

Results

Adipose tissue released large quantities of inactive LPL (p<0.001); skeletal muscle released small amounts of active LPL (p<0.01). Rosiglitazone increased adipose tissue release of LPL mass (+35%, p=0.04) and decreased the release of active LPL from skeletal muscle (−57%, p=0.03). Rosiglitazone increased adipose tissue and skeletal muscle LPL mRNA, but did not affect adipose tissue LPL rate of action or activity. Adipose tissue release of LPL mass correlated with systemic LPL mass concentrations (r=0.47, p=0.007), suggesting that the rate of adipose tissue release of LPL mass is a major determinant of systemic LPL mass concentrations.

Conclusions/interpretation

LPL transport from adipose tissue and skeletal muscle are regulated differently. In adipose tissue, rosiglitazone increases LPL mRNA abundance and LPL transport rate and possibly increases endothelial binding sites for LPL, but affects neither tissue LPL activity nor LPL rate of action.
Literatur
1.
Zurück zum Zitat Simsolo RB, Ong JM, Saffari B, Kern PA (1992) Effect of improved diabetes control on the expression of lipoprotein lipase in human adipose tissue. J Lipid Res 33:89–95PubMed Simsolo RB, Ong JM, Saffari B, Kern PA (1992) Effect of improved diabetes control on the expression of lipoprotein lipase in human adipose tissue. J Lipid Res 33:89–95PubMed
2.
Zurück zum Zitat Taskinen MR, Nikkila EA, Kuusi T, Harmo K (1982) Lipoprotein lipase activity and serum lipoproteins in untreated type 2 (insulin-independent) diabetes associated with obesity. Diabetologia 22:46–50PubMedCrossRef Taskinen MR, Nikkila EA, Kuusi T, Harmo K (1982) Lipoprotein lipase activity and serum lipoproteins in untreated type 2 (insulin-independent) diabetes associated with obesity. Diabetologia 22:46–50PubMedCrossRef
3.
Zurück zum Zitat Taskinen MR, Nikkila EA, Nousiainen R, Gordin A (1981) Lipoprotein lipase activity in adipose tissue and skeletal muscle of human diabetics during insulin deprivation and restoration. Scand J Clin Lab Invest 41:263–268PubMed Taskinen MR, Nikkila EA, Nousiainen R, Gordin A (1981) Lipoprotein lipase activity in adipose tissue and skeletal muscle of human diabetics during insulin deprivation and restoration. Scand J Clin Lab Invest 41:263–268PubMed
4.
Zurück zum Zitat Nikkila EA, Huttunen JK, Ehnholm C (1977) Postheparin plasma lipoprotein lipase and hepatic lipase in diabetes mellitus. Relationship to plasma triglyceride metabolism. Diabetes 26:11–21PubMedCrossRef Nikkila EA, Huttunen JK, Ehnholm C (1977) Postheparin plasma lipoprotein lipase and hepatic lipase in diabetes mellitus. Relationship to plasma triglyceride metabolism. Diabetes 26:11–21PubMedCrossRef
5.
Zurück zum Zitat Miyashita Y, Shirai K, Itoh Y et al (2002) Low lipoprotein lipase mass in preheparin serum of type 2 diabetes mellitus patients and its recovery with insulin therapy. Diabetes Res Clin Pract 56:181–187PubMedCrossRef Miyashita Y, Shirai K, Itoh Y et al (2002) Low lipoprotein lipase mass in preheparin serum of type 2 diabetes mellitus patients and its recovery with insulin therapy. Diabetes Res Clin Pract 56:181–187PubMedCrossRef
6.
Zurück zum Zitat Hanyu O, Miida T, Obayashi K et al (2004) Lipoprotein lipase (LPL) mass in preheparin serum reflects insulin sensitivity. Atherosclerosis 174:385–390PubMed Hanyu O, Miida T, Obayashi K et al (2004) Lipoprotein lipase (LPL) mass in preheparin serum reflects insulin sensitivity. Atherosclerosis 174:385–390PubMed
7.
Zurück zum Zitat Bengtsson-Olivecrona G, Olivecrona T (1992) Assay of lipoprotein lipase and hepatic lipase. Oxford University Press, Oxford, pp 170–184 Bengtsson-Olivecrona G, Olivecrona T (1992) Assay of lipoprotein lipase and hepatic lipase. Oxford University Press, Oxford, pp 170–184
8.
Zurück zum Zitat Miyashita Y, Shirai K (2005) Clinical determination of the severity of metabolic syndrome: preheparin lipoprotein lipase mass as a new marker of metabolic syndrome. Curr Med Chem Cardiovasc Hematol Agents 3:377–381PubMedCrossRef Miyashita Y, Shirai K (2005) Clinical determination of the severity of metabolic syndrome: preheparin lipoprotein lipase mass as a new marker of metabolic syndrome. Curr Med Chem Cardiovasc Hematol Agents 3:377–381PubMedCrossRef
9.
Zurück zum Zitat Rip J, Nierman MC, Wareham NJ et al (2006) Serum lipoprotein lipase concentration and risk for future coronary artery disease. The EPIC-Norfolk Prospective Population Study. Arterioscler Thromb Vasc Biol 26:637–642PubMedCrossRef Rip J, Nierman MC, Wareham NJ et al (2006) Serum lipoprotein lipase concentration and risk for future coronary artery disease. The EPIC-Norfolk Prospective Population Study. Arterioscler Thromb Vasc Biol 26:637–642PubMedCrossRef
10.
Zurück zum Zitat Merkel M, Eckel RH, Goldberg IJ (2002) Lipoprotein lipase: genetics, lipid uptake, and regulation. J Lipid Res 43:1997–2006PubMedCrossRef Merkel M, Eckel RH, Goldberg IJ (2002) Lipoprotein lipase: genetics, lipid uptake, and regulation. J Lipid Res 43:1997–2006PubMedCrossRef
11.
Zurück zum Zitat Mead JR, Irvine SA, Ramji DP (2002) Lipoprotein lipase: structure, function, regulation, and role in disease. J Mol Med 80:753–769PubMedCrossRef Mead JR, Irvine SA, Ramji DP (2002) Lipoprotein lipase: structure, function, regulation, and role in disease. J Mol Med 80:753–769PubMedCrossRef
12.
Zurück zum Zitat Wu G, Brouckaert P, Olivecrona T (2004) Rapid downregulation of adipose tissue lipoprotein lipase activity on food deprivation: evidence that TNF-alpha is involved. Am J Physiol Endocrinol Metab 286:E711–E717PubMedCrossRef Wu G, Brouckaert P, Olivecrona T (2004) Rapid downregulation of adipose tissue lipoprotein lipase activity on food deprivation: evidence that TNF-alpha is involved. Am J Physiol Endocrinol Metab 286:E711–E717PubMedCrossRef
13.
Zurück zum Zitat Ong JM, Kern PA (1989) Effect of feeding and obesity on lipoprotein lipase activity, immunoreactive protein, and messenger RNA levels in human adipose tissue. J Clin Invest 84:305–311PubMedCrossRef Ong JM, Kern PA (1989) Effect of feeding and obesity on lipoprotein lipase activity, immunoreactive protein, and messenger RNA levels in human adipose tissue. J Clin Invest 84:305–311PubMedCrossRef
14.
Zurück zum Zitat Bergo M, Wu G, Ruge T, Olivecrona T (2002) Down-regulation of adipose tissue lipoprotein lipase during fasting requires that a gene, separate from the lipase gene, is switched on. J Biol Chem 277:11927–11932PubMedCrossRef Bergo M, Wu G, Ruge T, Olivecrona T (2002) Down-regulation of adipose tissue lipoprotein lipase during fasting requires that a gene, separate from the lipase gene, is switched on. J Biol Chem 277:11927–11932PubMedCrossRef
15.
Zurück zum Zitat Wu G, Olivecrona G, Olivecrona T (2005) Extracellular degradation of lipoprotein lipase in rat adipose tissue. BMC Cell Biol 6:4PubMedCrossRef Wu G, Olivecrona G, Olivecrona T (2005) Extracellular degradation of lipoprotein lipase in rat adipose tissue. BMC Cell Biol 6:4PubMedCrossRef
16.
Zurück zum Zitat Ruge T, Bergo M, Hultin M, Olivecrona G, Olivecrona T (2000) Nutritional regulation of binding sites for lipoprotein lipase in rat heart. Am J Physiol Endocrinol Metab 278:E211–E218PubMed Ruge T, Bergo M, Hultin M, Olivecrona G, Olivecrona T (2000) Nutritional regulation of binding sites for lipoprotein lipase in rat heart. Am J Physiol Endocrinol Metab 278:E211–E218PubMed
17.
Zurück zum Zitat Karpe F, Olivecrona T, Olivecrona G et al (1998) Lipoprotein lipase transport in plasma: the role of muscle and adipose tissue in regulation of plasma lipoprotein lipase concentrations. J Lipid Res 39:2387–2393PubMed Karpe F, Olivecrona T, Olivecrona G et al (1998) Lipoprotein lipase transport in plasma: the role of muscle and adipose tissue in regulation of plasma lipoprotein lipase concentrations. J Lipid Res 39:2387–2393PubMed
18.
Zurück zum Zitat Tan GD, Fielding BA, Currie JM et al (2005) The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes. Diabetologia 48:83–95PubMedCrossRef Tan GD, Fielding BA, Currie JM et al (2005) The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes. Diabetologia 48:83–95PubMedCrossRef
19.
Zurück zum Zitat Frayn KN, Coppack SW (2001) Assessment of white adipose tissue metabolism by measurement of arteriovenous differences. Methods Mol Biol 155:269–279PubMed Frayn KN, Coppack SW (2001) Assessment of white adipose tissue metabolism by measurement of arteriovenous differences. Methods Mol Biol 155:269–279PubMed
20.
Zurück zum Zitat Holm C, Olivecrona G, Ottosson M (2001) Assays of lipolytic enzymes. Methods Mol Biol 155:97–119PubMed Holm C, Olivecrona G, Ottosson M (2001) Assays of lipolytic enzymes. Methods Mol Biol 155:97–119PubMed
21.
Zurück zum Zitat Tornvall P, Olivecrona G, Karpe F, Hamsten A, Olivecrona T (1995) Lipoprotein mass and activity in plasma and their increase after heparin are separate parameters with different relations to plasma lipoproteins. Arterioscler Thromb Vasc Biol 15:1086–1093PubMed Tornvall P, Olivecrona G, Karpe F, Hamsten A, Olivecrona T (1995) Lipoprotein mass and activity in plasma and their increase after heparin are separate parameters with different relations to plasma lipoproteins. Arterioscler Thromb Vasc Biol 15:1086–1093PubMed
22.
Zurück zum Zitat Eriksson JW, Buren J, Svensson M, Olivecrona T, Olivecrona G (2003) Postprandial regulation of blood lipids and adipose tissue lipoprotein lipase in type 2 diabetes patients and healthy control subjects. Atherosclerosis 166:359–367PubMedCrossRef Eriksson JW, Buren J, Svensson M, Olivecrona T, Olivecrona G (2003) Postprandial regulation of blood lipids and adipose tissue lipoprotein lipase in type 2 diabetes patients and healthy control subjects. Atherosclerosis 166:359–367PubMedCrossRef
23.
Zurück zum Zitat Lookene A, Savonen R, Olivecrona G (1997) Interaction of lipoproteins with heparan sulfate proteoglycans and with lipoprotein lipase. Studies by surface plasmon resonance technique. Biochemistry 36:5267–5275PubMedCrossRef Lookene A, Savonen R, Olivecrona G (1997) Interaction of lipoproteins with heparan sulfate proteoglycans and with lipoprotein lipase. Studies by surface plasmon resonance technique. Biochemistry 36:5267–5275PubMedCrossRef
24.
Zurück zum Zitat Lookene A, Zhang L, Hultin M, Olivecrona G (2004) Rapid subunit exchange in dimeric lipoprotein lipase and properties of the inactive monomer. J Biol Chem 279:49964–49972PubMedCrossRef Lookene A, Zhang L, Hultin M, Olivecrona G (2004) Rapid subunit exchange in dimeric lipoprotein lipase and properties of the inactive monomer. J Biol Chem 279:49964–49972PubMedCrossRef
25.
Zurück zum Zitat Reizes O, Goldberger O, Smith AC, Xu Z, Bernfield M, Bickel PE (2006) Insulin promotes shedding of syndecan ectodomains from 3T3-L1 adipocytes: a proposed mechanism for stabilization of extracellular lipoprotein lipase. Biochemistry 45:5703–5711PubMedCrossRef Reizes O, Goldberger O, Smith AC, Xu Z, Bernfield M, Bickel PE (2006) Insulin promotes shedding of syndecan ectodomains from 3T3-L1 adipocytes: a proposed mechanism for stabilization of extracellular lipoprotein lipase. Biochemistry 45:5703–5711PubMedCrossRef
26.
Zurück zum Zitat Shirai K, Itoh Y, Sasaki H et al (1999) The effect of insulin sensitizer, troglitazone, on lipoprotein lipase mass in preheparin serum. Diabetes Res Clin Pract 46:35–41PubMedCrossRef Shirai K, Itoh Y, Sasaki H et al (1999) The effect of insulin sensitizer, troglitazone, on lipoprotein lipase mass in preheparin serum. Diabetes Res Clin Pract 46:35–41PubMedCrossRef
27.
Zurück zum Zitat Nagashima K, Lopez C, Donovan D et al (2005) Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. J Clin Invest 115:1323–1332PubMedCrossRef Nagashima K, Lopez C, Donovan D et al (2005) Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. J Clin Invest 115:1323–1332PubMedCrossRef
Metadaten
Titel
Insulin sensitisation affects lipoprotein lipase transport in type 2 diabetes: role of adipose tissue and skeletal muscle in response to rosiglitazone
verfasst von
G. D. Tan
G. Olivecrona
H. Vidal
K. N. Frayn
F. Karpe
Publikationsdatum
01.10.2006
Verlag
Springer-Verlag
Erschienen in
Diabetologia / Ausgabe 10/2006
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-006-0370-9

Weitere Artikel der Ausgabe 10/2006

Diabetologia 10/2006 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.